Press release – Landmark deal to boost nation’s health and save NHS £14 billion – 2024 voluntary scheme for branded medicines pricing, access and growth
New voluntary scheme for branded medicines pricing, access and growth (VPAG) will boost nation’s health, save NHS £14 billion and support research investment. This scheme is an agreement between DHSC, NHS England and ABPI to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector.
What is it for?
- Deal agreed by government, NHS England and pharmaceutical industry will improve access to cutting-edge treatments for NHS patients, support financial sustainability of the health service and advance UK life sciences sector
- Pro-innovation and pro-competition agreement will introduce a new mechanism to support lower industry payment rates for more innovative and pioneering branded medicines
- Significant industry investment in UK clinical trials, manufacturing and health technology assessments strengthens UK’s global competitiveness
Published on the 20th of november 2023. For more information on this press release read the entire news report here.
Find out more on this news scheme by reading the policy paper on the 2024 voluntary scheme for branded medicines pricing, access and growth: summary of the heads of agreement – GOV.UK (www.gov.uk). Follow this link published on the 14th of december 2023 to have access to the documents regarding this scheme.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (21 mai 2024). Press release – Landmark deal to boost nation’s health and save NHS £14 billion – 2024 voluntary scheme for branded medicines pricing, access and growth. ELSIBI. Consulté le 12 janvier 2026 à l’adresse https://doi.org/10.58079/11owp





